Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma‐derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients ha...

Descripción completa

Detalles Bibliográficos
Autores principales: van Velzen, Alice S., Eckhardt, Corien L., Peters, Marjolein, Oldenburg, Johannes, Cnossen, Marjon, Liesner, Ri, Morfini, Massimo, Castaman, Giancarlo, McRae, Simon, van der Bom, Johanna G., Fijnvandraat, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Platelets, Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318706/
https://www.ncbi.nlm.nih.gov/pubmed/32201943
http://dx.doi.org/10.1111/bjh.16490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318706/
https://www.ncbi.nlm.nih.gov/pubmed/32201943
http://dx.doi.org/10.1111/bjh.16490

Ejemplares similares